Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists

NCT00126724 is registered in ClinicalTrials.gov with Targeted Genetics Corporation as lead sponsor.

NCT NCT00126724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists
Lead sponsor
Targeted Genetics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2005
Completion date
May 31, 2009
Enrollment
120 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, arthritis, psoriatic, arthritis, rheumatoid